poisar

Stock

Precision BioSciences, Inc. DTIL

$7.33+0.07%

Overview

DTIL market data

Price History

DTIL price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.56
Diluted earnings per share over the trailing twelve months.
Beta
1.27
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.53 – $9.62
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $190.2 · P/B 1.09 · P/S 4.22.

Company news

10 captured
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026Benzinga · Jul 1, 2026, 11:35 AM
8-K filing — PRECISION BIOSCIENCES INC (DTIL)SEC EDGAR · Jul 1, 2026, 11:17 AM
Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20Benzinga · Jun 9, 2026, 11:40 AM
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price TargetBenzinga · May 27, 2026, 4:40 PM
Why Is Precision BioSciences Stock Gaining Wednesday?Benzinga · May 27, 2026, 12:31 PM
Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B StudyBenzinga · May 27, 2026, 7:30 AM
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · May 26, 2026, 5:15 PM
Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B TrialBenzinga · May 21, 2026, 11:20 AM
Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual MeetingBenzinga · May 14, 2026, 11:14 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock